Chun Yin, Ying Wang, Hao Yang, Gaoshan Li, Zhichun Gao, Kunyan Li, Guiquan Zhou, Xuan Zhang, Xiangzheng Xu, Hu Tan, Jun Jin
{"title":"Association of mitochondrial DNA copy number in peripheral blood with risk and prognosis in acute aortic syndrome.","authors":"Chun Yin, Ying Wang, Hao Yang, Gaoshan Li, Zhichun Gao, Kunyan Li, Guiquan Zhou, Xuan Zhang, Xiangzheng Xu, Hu Tan, Jun Jin","doi":"10.1016/j.jmoldx.2024.12.009","DOIUrl":null,"url":null,"abstract":"<p><p>Previous studies have reported that mtDNA-CN of blood was associated with a series of aging-related diseases. However, it remains unknown whether mtDNA-CN can be a potential biomarker of acute aortic syndromes (AAS). The mtDNA-CN in blood of 190 male patients with AAS and 207 healthy controls were detected by standardized qPCR-based assay. The mtDNA sequencing data of blood and myocardial muscle in 134 individuals were used to analyze mtDNA somatic mutations in blood. MtDNA-CN in peripheral blood was negatively correlated with age of individuals. Further analysis based on NGS data demonstrated numbers and heteroplasmy of mtDNA mutations were positively correlated with age. Remarkably, mtDNA-CN of AAS patients was lower than that of healthy controls. Logistic regression also showed that mtDNA-CN was independently associated with risk of AAS. During follow-up, patients with the lowest mtDNA-CN quartile had HR of 2.543 for all-cause-mortality and 1.964 for composite endpoints compared with the other patients. Moreover, multivariate COX regression indicated that lowest mtDNA-CN quartile was independently associated with all-cause mortality in AAS patients. Our study demonstrated a negative correlation between mtDNA-CN and age. Moreover, lower mtDNA-CN in peripheral blood was significantly associated with higher risk and worse prognosis of AAS. It provided crucial evidence supporting the potential of mtDNA-CN as a novel biomarker of AAS.</p>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jmoldx.2024.12.009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Previous studies have reported that mtDNA-CN of blood was associated with a series of aging-related diseases. However, it remains unknown whether mtDNA-CN can be a potential biomarker of acute aortic syndromes (AAS). The mtDNA-CN in blood of 190 male patients with AAS and 207 healthy controls were detected by standardized qPCR-based assay. The mtDNA sequencing data of blood and myocardial muscle in 134 individuals were used to analyze mtDNA somatic mutations in blood. MtDNA-CN in peripheral blood was negatively correlated with age of individuals. Further analysis based on NGS data demonstrated numbers and heteroplasmy of mtDNA mutations were positively correlated with age. Remarkably, mtDNA-CN of AAS patients was lower than that of healthy controls. Logistic regression also showed that mtDNA-CN was independently associated with risk of AAS. During follow-up, patients with the lowest mtDNA-CN quartile had HR of 2.543 for all-cause-mortality and 1.964 for composite endpoints compared with the other patients. Moreover, multivariate COX regression indicated that lowest mtDNA-CN quartile was independently associated with all-cause mortality in AAS patients. Our study demonstrated a negative correlation between mtDNA-CN and age. Moreover, lower mtDNA-CN in peripheral blood was significantly associated with higher risk and worse prognosis of AAS. It provided crucial evidence supporting the potential of mtDNA-CN as a novel biomarker of AAS.
期刊介绍:
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology (AMP), co-owned by the American Society for Investigative Pathology (ASIP), seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, clinical informatics, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods which may be applied to diagnosis or monitoring of disease or disease predisposition.